Meeting
2015 ASCO Annual Meeting
Validation of correlation of RECIST changes with survival in metastatic castration-resistant prostate cancer (mCRPC).
Authors
Gregory Russell Pond
Ontario Clinical Oncology Group (OCOG), Hamilton, ON, Canada
Gregory Russell Pond , Arnoud J. Templeton , Daniel Peter Petrylak , Abderrahim Fandi , Bertrand F. TOMBAL , Mark Rosenthal , Guru Sonpavde
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer
Sub Track
Prostate Cancer
Citation
J Clin Oncol 33, 2015 (suppl; abstr 5057)
DOI
10.1200/jco.2015.33.15_suppl.5057
Abstract #
5057
Poster Bd #
51
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Validation of the association of RECIST 1.0 changes with survival in men with metastatic castration resistant prostate cancer (mCRPC) treated on SWOG Study S0421.
First Author: Gregory Russell Pond
Poster
2015 Genitourinary Cancers Symposium
Association of changes in measurable disease by RECIST with survival in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Guru Sonpavde
Poster
2020 ASCO Virtual Scientific Program
Pembrolizumab (pembro) plus docetaxel and prednisone in patients (pts) with abiraterone acetate (abi) or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B efficacy, safety and, biomarker results.
First Author: Srikala S. Sridhar
Poster
2020 Genitourinary Cancers Symposium
Phase III study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone acetate (abi)–pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-921.
First Author: Daniel Peter Petrylak